Pinetree Therapeutics, Inc., a trailblazer in targeted protein degradation (TPD) technology, has successfully closed a Series A funding round, raising $17 million to advance its AbReptor™ platform. This investment round was co-led by STIC Investments and DSC Investment, with new participation from Atinum Investment, Quantum FA, and S&S Investment, alongside existing backers DSC Investment, Schmidt, and SGI Partners.
The newly acquired funds will be pivotal in furthering Pinetree’s AbReptor™ technology, which employs innovative multispecific antibody degraders aimed at overcoming drug resistance in oncology and other therapeutic areas. The company’s lead preclinical candidate, designed for EGFR-mutated cancers, recently garnered significant attention with an exclusive global license agreement with AstraZeneca.
Dr. Hojuhn Song, Founder and CEO of Pinetree Therapeutics, expressed enthusiasm about the funding: “Our AbReptor™ platform represents a breakthrough in targeted protein degradation, with the potential to address significant unmet medical needs. The recent partnership with AstraZeneca and this new round of funding position us well to advance our pipeline and explore new therapeutic avenues.”
Yohan Kim, Executive Director of DSC Investment, highlighted the confidence in Pinetree’s approach: “The impressive progress and promising data from Pinetree’s programs affirm our commitment to supporting their innovative technology. We look forward to seeing their continued success and impact on treatment-resistant diseases.”
Editorial Perspective: Pinetree Therapeutics is demonstrating a remarkable trajectory in the biotech field, particularly in addressing drug resistance, a major challenge in oncology. The AbReptor™ platform’s unique mechanism of action offers a novel approach to tackling complex diseases, potentially transforming treatment paradigms. The strategic partnership with AstraZeneca underscores the technology’s promise, and the latest funding will undoubtedly accelerate development and broaden its application. This company is poised to make significant strides in personalized medicine and beyond.
For further assistance or corrections, please reach out to editor@thetimesmag.com.
